NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis $30.21 +0.68 (+2.30%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$30.45 +0.24 (+0.80%) As of 06/9/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About QuidelOrtho Stock (NASDAQ:QDEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get QuidelOrtho alerts:Sign Up Key Stats Today's Range$29.89▼$30.9450-Day Range$24.46▼$37.4252-Week Range$23.77▼$49.45Volume1.03 million shsAverage Volume1.09 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$44.33Consensus RatingHold Company OverviewQuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More… QuidelOrtho Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreQDEL MarketRank™: QuidelOrtho scored higher than 92% of companies evaluated by MarketBeat, and ranked 151st out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageQuidelOrtho has only been the subject of 3 research reports in the past 90 days.Read more about QuidelOrtho's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.57% Earnings GrowthEarnings for QuidelOrtho are expected to grow by 39.57% in the coming year, from $2.30 to $3.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about QuidelOrtho's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.35% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently decreased by 1.40%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.61 Percentage of Shares Shorted6.35% of the float of QuidelOrtho has been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently decreased by 1.40%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.65 News SentimentQuidelOrtho has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for QuidelOrtho this week, compared to 7 articles on an average week.Search Interest8 people have searched for QDEL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about QuidelOrtho's insider trading history. Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address QDEL Stock News HeadlinesQuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9June 9 at 1:18 PM | gurufocus.comQuidelOrtho (NASDAQ:QDEL) Upgraded at Wall Street ZenJune 9 at 2:33 AM | americanbankingnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.It could very well mark the beginning of a new multitrillion-dollar industrial revolution. Up until now, we've imagined robots doing things like cleaning our homes, serving drinks at restaurants, greeting guests in hotel lobbies, stacking shelves in warehouses, and so on. Very soon, there will be a robot that won't do any of that. However, it's impact on the US economy and society will be FAR greater than anything we ever imagined.June 10, 2025 | Weiss Ratings (Ad)QuidelOrtho Declares that its Molecular Diagnostics Approach will be RefocusedJune 4, 2025 | insidermonkey.comQuidelOrtho to discontinue Savanna platform developmentJune 3, 2025 | msn.comQuidelOrtho (QDEL) to Acquire LEX Diagnostics Amid Strategic ShiftJune 3, 2025 | gurufocus.comQuidelOrtho Corp (QDEL) Announces Strategic Shift in Molecular Diagnostics | QDEL stock newsJune 3, 2025 | gurufocus.comQuidelOrtho Announces Strategy to Accelerate Growth in Molecular DiagnosticsJune 3, 2025 | prnewswire.comSee More Headlines QDEL Stock Analysis - Frequently Asked Questions How have QDEL shares performed this year? QuidelOrtho's stock was trading at $44.55 at the beginning of the year. Since then, QDEL shares have decreased by 32.2% and is now trading at $30.21. View the best growth stocks for 2025 here. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) announced its earnings results on Wednesday, May, 7th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.61 by $0.13. QuidelOrtho's quarterly revenue was down 2.6% on a year-over-year basis. Read the conference call transcript. Who are QuidelOrtho's major shareholders? Top institutional investors of QuidelOrtho include T. Rowe Price Investment Management Inc. (16.97%), Vanguard Group Inc. (10.01%), Invesco Ltd. (5.65%) and AQR Capital Management LLC (3.94%). Insiders that own company stock include Brian J Blaser, Joseph M Busky and Carlyle Group Inc. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some other companies that QuidelOrtho investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Salesforce (CRM) and CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2025Today6/10/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,000Year Founded1979Price Target and Rating Average Stock Price Target$44.33 High Stock Price Target$61.00 Low Stock Price Target$25.00 Potential Upside/Downside+46.8%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.97) Trailing P/E RatioN/A Forward P/E Ratio13.13 P/E GrowthN/ANet Income-$2.03 billion Net Margins-72.84% Pretax Margin-76.59% Return on Equity3.78% Return on Assets1.80% Debt Debt-to-Equity Ratio0.71 Current Ratio1.22 Quick Ratio0.69 Sales & Book Value Annual Sales$2.76 billion Price / Sales0.74 Cash Flow$23.42 per share Price / Cash Flow1.29 Book Value$44.75 per share Price / Book0.68Miscellaneous Outstanding Shares67,626,000Free Float66,584,000Market Cap$2.04 billion OptionableOptionable Beta0.10 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:QDEL) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Imagine you're driving down I-45 between Dallas and Houston. You come up behind an 18-wheeler, flick your s...Weiss Ratings | SponsoredWall Street Legend: Crash coming in March—details hereBad News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history give...Chaikin Analytics | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share QuidelOrtho With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.